Eli Lilly (LLY) Acquires Vaccine Firms for $3.8 Billion Growth Strategy
Published on · Source: finance.yahoo.com
AI Summary
Summarized by AI from the source belowEli Lilly (LLY) reported approximately $12.8 billion in revenues for Q1 2026, with its key drugs Mounjaro and Zepbound experiencing year-over-year sales growth of 125% and 80%, respectively. The company has invested $3.8 billion to acquire Curevo, LimmaTech Biologics AG, and Vaccine Company to expand its presence in infectious diseases. Eli Lilly's current P/E ratio stands at 39x, significantly higher than the pharmaceutical sector average of 24x. This strategic move is seen as a way to diversify its portfolio as the patent protection on its GLP-1 drugs is time-limited.
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
About Eli Lilly and Company (LLY)
Eli Lilly is a major pharmaceutical company known for diabetes and obesity treatments and a broad drug pipeline.
The Health Care sector covers pharmaceutical, biotech, device and managed-care companies.
Earlier LLY news
- Eli Lilly (LLY) shares phase 3 data on weight loss drug retatrutide
- CVS (CVS) Restores Coverage of Zepbound, Adds Eli Lilly's Foundayo
- IHE vs IXJ: 39.7% vs 10% 1-Year Returns in ETFs Comparison
- Eli Lilly (LLY) plans nearly $4 billion vaccine acquisitions
- Eli Lilly (LLY) Stock Rating Reiterated Amid Gene Therapy Progress
Get the weekly market brief
One email every Monday: what moved, why, and what to watch. Free, unsubscribe anytime.
Get stories like this as they break
Our Telegram channel posts every market story the moment it is published. Free, and you can mute or leave anytime.
Related News
Logistea Q3 2026 Shows 19% Income Growth and SEK 3.6bn Acquisitions
Oct 22
IG Group Reaffirms Guidance and Adopts Credit Rating Framework
Oct 22
Vimian (VMI) Q3 2026 Reports 15% Revenue Growth and Strong Cash Flow
Oct 22
IHG Q3 Revenue Per Room Beats Forecast but Shares Slip
Oct 22